Proliferative Diabetic Retinopathy Market to Reach USD 7.8 Billion by 2036, Fueled by Rising Diabetes Prevalence and Advances in Long-Acting Retinal Therapies - TMR

The global proliferative diabetic retinopathy market was valued at approximately USD 3.1 billion in 2025 and is projected to reach USD 7.8 billion by 2036, expanding at a CAGR of 9.7% from 2026 to 2036. Market growth is being supported by the increasing global prevalence of diabetes, the growing burden of vision-threatening diabetic eye disease, wider adoption of retinal screening, and continued advances in ophthalmic therapeutics. Increasing awareness of early diagnosis and greater access to specialized ophthalmology services are also contributing to demand for effective treatments for advanced diabetic retinal disease.

Market Overview

Proliferative diabetic retinopathy is an advanced stage of diabetic eye disease in which abnormal blood vessels develop on or around the retina. These fragile vessels can bleed into the vitreous, contribute to retinal scarring and detachment, and ultimately cause severe vision impairment or blindness if left untreated. The growing incidence of diabetes is therefore creating a larger patient population requiring regular retinal monitoring, specialist intervention, and long-term disease management.

The treatment landscape is evolving around anti-VEGF agents, corticosteroids, injectable therapies, and emerging sustained-delivery technologies. Anti-VEGF therapy remains a major treatment approach because vascular endothelial growth factor plays a central role in abnormal blood-vessel formation and vascular leakage associated with diabetic retinal disease. Increasing use of intravitreal therapies, improvements in retinal imaging, and greater emphasis on early intervention are expected to sustain market growth during the forecast period.

North America dominated the global market in 2025, accounting for approximately 42.0% of revenue. The region benefits from a substantial diabetes population, established ophthalmology infrastructure, specialized retina-care centers, availability of advanced therapies, and comparatively strong access to retinal diagnostics and treatment.

Access key findings and insights from our Report in this sample -

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=40637 

Key Market Growth Drivers

The increasing prevalence of diabetes is one of the most important factors driving the proliferative diabetic retinopathy market. Long-term diabetes can damage the small blood vessels supplying the retina, increasing the risk of diabetic retinopathy and its advanced forms. As the global diabetic population expands, demand is expected to increase for retinal screening, monitoring, diagnosis, and treatment. Greater awareness of diabetes-related vision complications is also encouraging patients and healthcare providers to prioritize early detection and intervention.

The rising number of vision-threatening diabetic retinopathy cases is further strengthening demand for specialized retinal therapies. Patients with advanced disease may require anti-VEGF injections, corticosteroid-based treatment, laser procedures, surgery, or combinations of these approaches depending on disease characteristics and clinical requirements. Expanding screening programs and improvements in retinal imaging can help identify high-risk patients earlier, increasing the need for ophthalmology services and therapeutic interventions.

Another important growth factor is the increasing focus on reducing treatment burden. Traditional intravitreal treatment can require repeated injections and frequent specialist visits, creating challenges for patients, caregivers, and healthcare providers. Pharmaceutical companies are consequently investing in longer-acting therapies and sustained-release drug delivery technologies designed to extend treatment intervals and support adherence.

Analysis of Key Players – Key Player Strategies

The competitive landscape includes major pharmaceutical companies and specialized ophthalmology developers with established retinal disease portfolios. Leading participants include F. Hoffmann-La Roche Ltd., Genentech, Inc., Regeneron Pharmaceuticals, Inc., Novartis AG, Bayer AG, AbbVie Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co., Ltd., ANI Pharmaceuticals, Inc., Pfizer Inc., Merck KGaA, Cipla Inc., Intas Pharmaceuticals Ltd., EyePoint Pharmaceuticals, Inc., Kodiak Sciences Inc., Oculis Holding AG, REGENXBIO Inc., Opthea Limited, Clearside Biomedical, Inc., and Oxurion NV.

Companies are competing through product innovation, clinical development, regulatory approvals, expanded ophthalmology portfolios, strategic collaborations, and investments in therapies capable of providing longer-lasting disease control. Particular attention is being directed toward next-generation anti-VEGF products, sustained-release delivery platforms, corticosteroid implants, and technologies designed to reduce the frequency of retinal injections.

Market Challenges & Opportunities

The market continues to face challenges related to the treatment burden associated with repeated intravitreal injections, patient adherence, healthcare accessibility, treatment costs, and differences in reimbursement and regulatory environments. The need for specialized retina-care professionals can also restrict access to advanced therapies in regions where ophthalmology infrastructure is less developed. Furthermore, long-term management of diabetic retinal disease requires continued patient monitoring, making treatment continuity an important consideration for healthcare systems.

These challenges are simultaneously creating opportunities for pharmaceutical and biotechnology companies developing longer-acting retinal therapies. Sustained-release drug delivery, implantable systems, improved formulations, and therapies that extend dosing intervals could help address adherence challenges while improving the convenience of long-term disease management. Expanding retinal screening programs and digital imaging technologies also offer opportunities to improve patient identification and referral to specialist care, particularly in emerging markets.

Key Player Strategies

Leading companies are increasingly emphasizing differentiated therapies that can improve treatment durability and reduce the frequency of interventions. Roche, for example, has continued to develop its ophthalmology portfolio around products and delivery technologies designed to address retinal diseases while reducing treatment burden. In May 2025, Roche announced U.S. FDA approval of Susvimo for diabetic retinopathy, highlighting the potential of continuous drug delivery and longer treatment intervals.

In April 2026, Roche announced plans to present extensive ophthalmology data at ARVO 2026, including real-world data concerning Vabysmo in diabetic macular edema and data related to Susvimo. Regeneron has likewise continued to advance its retinal disease portfolio, including clinical presentations concerning EYLEA HD at the Angiogenesis, Exudation, and Degeneration 2026 meeting. Such developments demonstrate the industry's broader shift toward higher-duration therapies and differentiated treatment platforms.

Explore our report to uncover in-depth insights -

https://www.transparencymarketresearch.com/proliferative-diabetic-retinopathy-market.html 

Investment Landscape and ROI Outlook

The proliferative diabetic retinopathy market presents attractive long-term investment opportunities across pharmaceutical therapies, drug-delivery technologies, retinal imaging, diagnostic platforms, and specialized ophthalmology services. The market's projected expansion from USD 3.1 billion in 2025 to USD 7.8 billion by 2036 reflects a substantial opportunity for companies with differentiated clinical assets and scalable commercial platforms.

Investment interest is likely to remain concentrated around therapies capable of addressing significant unmet needs, particularly products that improve treatment durability, reduce injection frequency, and enhance patient adherence. Companies with strong clinical evidence, established ophthalmology portfolios, regulatory expertise, and access to specialized distribution networks may be better positioned to capture market share. Potential returns will depend on clinical outcomes, regulatory success, reimbursement conditions, commercialization capabilities, and the ability to demonstrate meaningful advantages over established retinal therapies.

Market Segmentations

The global proliferative diabetic retinopathy market is segmented by drug class into anti-VEGF agents and corticosteroids, by mode of administration into injectable, oral, and other routes, and by application into treatment of proliferative diabetic retinopathy, diabetic macular edema management, retinal neovascularization management, vision loss prevention, and post-surgical disease management. Anti-VEGF therapy represented the leading drug class in 2025, accounting for approximately 57.0% of market revenue, supported by its established role in managing abnormal retinal blood-vessel growth and leakage.

The market is further segmented by end user into hospitals, ophthalmology clinics, retina specialty centers, ambulatory surgical centers, and other healthcare facilities. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Regionally, the market encompasses North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, with country-level analysis covering the U.S., Canada, Germany, the U.K., France, Italy, Spain, the Netherlands, Switzerland, China, India, Japan, South Korea, Australia and New Zealand, Brazil, Mexico, Argentina, GCC countries, and South Africa.

Why Buy This Report?

The proliferative diabetic retinopathy market report provides comprehensive analysis of market size, growth trends, competitive dynamics, therapeutic developments, regional performance, market opportunities, and emerging technologies through 2036. The study can help pharmaceutical companies, biotechnology firms, investors, healthcare providers, distributors, and other stakeholders evaluate growth opportunities and formulate informed business strategies.

The report also provides detailed analysis of key companies, including their business strategies, financial performance, product portfolios, ophthalmology pipelines, regulatory approvals, sales footprint, and recent developments. Its combination of quantitative market estimates and qualitative competitive analysis provides stakeholders with a structured view of the evolving diabetic retinal disease treatment landscape.

FAQs

What is the projected size of the proliferative diabetic retinopathy market? The global proliferative diabetic retinopathy market was valued at USD 3.1 billion in 2025 and is projected to reach USD 7.8 billion by 2036, growing at a CAGR of 9.7% during 2026–2036.

Which drug class dominates the market? Anti-VEGF therapy dominated the market in 2025, accounting for approximately 57.0% of global revenue. Its established role in managing abnormal retinal blood-vessel growth and leakage supports continued demand.

Which region leads the proliferative diabetic retinopathy market? North America led the global market in 2025 with approximately 42.0% of revenue. Its leadership is supported by a large diabetic population, advanced ophthalmology infrastructure, specialized retina-care services, and access to innovative retinal therapies.

What are the major factors driving market growth? Rising diabetes prevalence, increasing cases of vision-threatening diabetic retinopathy, broader retinal screening, greater access to ophthalmology services, and advances in intravitreal and long-acting therapies are the major factors supporting market expansion.

Who are the major companies in the market? Major participants include F. Hoffmann-La Roche Ltd., Genentech, Inc., Regeneron Pharmaceuticals, Inc., Novartis AG, Bayer AG, AbbVie Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co., Ltd., EyePoint Pharmaceuticals, Inc., Kodiak Sciences Inc., Oculis Holding AG, REGENXBIO Inc., Opthea Limited, and other pharmaceutical and biotechnology companies.

Buy this Premium Research Report for exclusive, in-depth insights -

https://www.transparencymarketresearch.com/checkout.php?rep_id=40637<ype=S 

More Trending Reports by Transparency Market Research -

Anti-Acne Dermal Patch Market

GCC Countries Vertical Lift Module Market

Folding Cartons Market

Influenza Vaccine Market

Computed Tomography (CT) Market

U.S. Nicotine Pouches Market

Cancer Biomarkers Market

Acetylene Market

Sleep Apnea Devices Market

Digital Signage Market

Skin Care Market

Autoinjectors Market

Activated Carbon Market

Propane Market

Neodymium Market

Atomic Force Microscopes (AFM) Market

Lithium-ion Battery Market

Fencing Market

Ceramic Sanitary Ware Market

Base Oil Market

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact:

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com 

Media Inquiries: media@transparencymarketresearch.com